Due to a production error, an author’s name was incorrectly spelled as “Taka-aki Mastuoka”. The correct spelling is “Taka-aki Matsuoka”. The publisher apologizes for this mistake.
The original version of this article has been updated.
Summary
Keywords
SARS-CoV-2, COVID-19, thyroid autoimmunity, BNT162b2 vaccine, thyroid-stimulating hormone receptor antibody, Graves’ disease
Citation
Frontiers Production Office (2023) Erratum: Effect of SARS-CoV-2 BNT162b2 mRNA vaccine on thyroid autoimmunity: a twelve-month follow-up study. Front. Endocrinol. 14:1257424. doi: 10.3389/fendo.2023.1257424
Received
12 July 2023
Accepted
12 July 2023
Published
24 July 2023
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
14 - 2023
Updates
Copyright
© 2023 Frontiers Production Office.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Frontiers Production Office, production.office@frontiersin.org
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.